文献速递青光眼

早期青光眼立即治疗与延迟治疗的长期影响:早期 Manifest 青光眼试验结果

Long-term Impact of Immediate Versus Delayed Treatment of Early Glaucoma: Results From the Early Manifest Glaucoma Trial.
PubMed 文献 · Am J Ophthalmol · 2023-05-02

早期 Manifest 青光眼试验(EMGT)长期随访比较立即治疗与延迟治疗对视觉功能的影响。255例新发现未治疗青光眼患者随机分入立即治疗组(倍他洛尔滴眼液联合氩激光小梁成形术)或无初始治疗组(直至发现进展)。结果显示延迟治疗未导致严重视觉功能损害,两组视觉损害比例无显著差异,对照组视野损害略多。

要点

  • 延迟治疗未导致严重视觉功能惩罚。
  • 视觉损害或盲的比例在治疗组略高,但差异无统计学意义。
  • 对照组视野损害略多于治疗组,但差异无统计学意义。

核心结论

  • 延迟治疗未导致严重惩罚;视觉损害在两组治疗臂中比例相似,治疗组略占优势,而视野损害在对照组略高。

研究设计与样本

  • 前瞻性随机对照临床试验的长期随访,在瑞典2个中心开展,255例新发现未治疗青光眼患者随机分入立即治疗组(倍他洛尔滴眼液联合氩激光小梁成形术)或无初始治疗组(直至发现进展),前瞻性随访长达21年。

主要发现

  • 研究结束时,视觉损害或盲眼的比例在治疗组略高于未治疗对照组,分别为12.1% vs 11.0%,以及9.4.% vs 6.1%,差异无统计学意义。
  • 至少一只眼视觉损害的受试者比例在治疗组为19.5% vs 对照组18.7%,差异无统计学意义,至少一只眼视觉损害的累积发病率也无显著差异。
  • 对照组视野丢失多于治疗组,较差眼的中位平均偏差(MD)为-14.73 dB vs -12.85 dB,进展速率为-0.74 vs -0.60 dB/y,差异无统计学意义。
  • 视力的差异极小。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare long-term visual outcomes in the 2 arms of the Early Manifest Glaucoma Trial (EMGT) and determine if delayed treatment was associated with a penalty in terms of visual function. DESIGN: Long-term follow-up of a prospective, randomized controlled clinical trial. METHODS: EMGT was carried out at 2 centers in Sweden; 255 subjects with newly detected, untreated glaucoma were randomized to immediate treatment with topical betaxolol and argon laser trabeculoplasty or to no initial treatment as long as no progression was detected. Subjects were followed prospectively with standard automated perimetry, visual acuity measurements, and tonometry for up to 21 years. Outcomes included vision impairment (VI), the perimetric mean deviation (MD) index and rate of progression, and visual acuity. RESULTS: At study end, percentages of eyes with VI or blindness were slightly higher in the treated group than in the untreated control group, 12.1% vs 11.0%, and 9.4.% vs 6.1% respectively, as were subjects with VI in at least one eye, 19.5% vs 18.7%. The differences were not statistically significant, nor were cumulative incidences of VI in at least one eye. The control group had more field loss than the treatment group, with median MD in the worse eye of -14.73 dB vs -12.85 dB, and rate of progression of -0.74 vs -0.60 dB/y, which was not statistically significant. Differences in visual acuity were minimal. CONCLUSIONS: Delaying treatment did not result in serious penalties. VI occurred at similar proportions in both treatment arms with a slight preponderance in the treatment group, whereas visual field damage was slightly higher in the control group.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Heijl A, Peters D, Bengtsson B, et al. Long-term Impact of Immediate Versus Delayed Treatment of Early Glaucoma: Results From the Early Manifest Glaucoma Trial. Am J Ophthalmol. 2023. PMID: 37142174. doi:10.1016/j.ajo.2023.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。